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Themammaliantargetof rapamycin(mTOR)positivelyregulatesaxongrowth inthemammaliancentralnervoussystem(CNS).Althoughaxon
regeneration and functional recovery from CNS injuries are typically limited, knockdown or deletion of PTEN, a negative regulator of mTOR,
increases mTOR activity and induces robust axon growth and regeneration. It has been suggested that inhibition of S6 kinase 1 (S6K1, gene
symbol: RPS6KB1), a prominentmTOR target, would bluntmTOR’s positive effect on axon growth. In contrast to this expectation, we demon-
strate that inhibitionofS6K1 inCNSneuronspromotesneuriteoutgrowth invitroby twofold to threefold.Biochemical analysis revealed that an
mTOR-dependent induction of PI3K signaling is involved inmediating this effect of S6K1 inhibition. Importantly, treating femalemice in vivo
withPF-4708671, a selective S6K1 inhibitor, stimulated corticospinal tract regeneration across adorsal spinal hemisectionbetween the cervical
5 and6cordsegments (C5/C6), increasingaxoncounts for at least 3mmbeyond the injury site at 8weeksafter injury.Concomitantly, treatment
withPF-4708671producedsignificant locomotorrecovery.Pharmacological targetingofS6K1maythereforeconstituteanattractivestrategyfor
promoting axon regeneration followingCNS injury, especially given that S6K1 inhibitors are being assessed in clinical trials for nononcological
indications.
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Introduction
The PI3K/mammalian target of rapamycin (mTOR) pathway is a
key regulator of axon growth and regeneration in the CNS (Park
et al., 2008). Typically, axons in the adult mammalian CNS have
limited capacity for regeneration following injury. Activating the
PI3K/mTOR pathway by knockdown or genetic deletion of its
negative regulator, PTEN, results in a marked increase in regen-
erative capacity (Zerhouni, 2004; Park et al., 2008, 2010; Zukor et
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Significance Statement
Despite mTOR’s well-established function in promoting axon regeneration, the role of its downstream target, S6 kinase 1 (S6K1),
has been unclear. We used cellular assays with primary neurons to demonstrate that S6K1 is a negative regulator of neurite
outgrowth, and a spinal cord injury model to show that it is a viable pharmacological target for inducing axon regeneration. We
providemechanistic evidence that S6K1’s negative feedback toPI3K signaling is involved in axongrowth inhibition, and show that
phosphorylation of S6K1 is a more appropriate regeneration indicator than is S6 phosphorylation.
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al., 2013), and mTOR activity is critical for the regeneration in-
duced by loss of PTEN (Park et al., 2010). The mechanisms
through which mTOR promotes axon growth/regeneration are
less clear; in particular, the role(s) of S6K1, a downstream effector
of mTOR, are incompletely understood (Hubert et al., 2014;
Yang et al., 2014).
We previously screened a large number of kinase inhibitors in
a neurite outgrowth assay using primary hippocampal neurons,
and identified “hit” compounds that promote neurite outgrowth
(Al-Ali et al., 2013b). This phenotypic assay is reliable (Z fac-
tor  0.7) and has identified both chemical and genetic pertur-
bagens that promote axon growth from a variety of CNS neurons
(Al-Ali et al., 2013a, 2017). In a follow-up study,we usedmachine
learning to relate data from the phenotypic screen of kinase in-
hibitors to kinase profiling data, which allowed us to identify
(and verify) “target” kinases whose inhibition induces neurite
outgrowth (Al-Ali et al., 2015). These target kinases included
representatives of the family of ribosomal S6 protein kinases
(RPS6Ks).
Two types of S6 kinases have been described based on their
domain topology: the p70 ribosomal S6 kinases (S6K1 and S6K2,
which phosphorylate S6 at S235/236/240/244/247) and the p90 ribo-
somal S6 kinases (RSK1, RSK2, RSK3, and RSK4, which phos-
phorylate S6 at S235/236) (Meyuhas, 2015). Two additional p90
kinases, MSK1 andMSK2, are included in the family by virtue of
sequence similarity (Pearce et al., 2010b) but do not appear to
have substantial activity toward S6. Previous studies have shown
that RSKs and MSKs negatively regulate neurite outgrowth (Loh
et al., 2008; Fischer et al., 2009; Buchser et al., 2010; Hubert et al.,
2014). Therefore, the finding that their inhibition promotes neu-
rite outgrowthmight be expected. The observation that neuronal
S6K1 activity may be negatively correlated with neurite out-
growth was interesting, however, given the well-established role
of its upstream activator mTOR as a positive regulator of axon
growth.
In dividing cells, S6K1 acts as a negative feedback regulator of
the PI3K/mTOR pathway, such that inhibition of S6K1 leads to
induction of PI3K signaling and subsequent activation of mTOR
(Pende et al., 2004;Umet al., 2004;Magnuson et al., 2012). In this
study, we show that a similar regulatory mechanism occurs in neu-
rons: inhibition of S6K1 induces neurite outgrowth in an mTOR-
dependentmanner. Importantly, we demonstrate that treatingmice
with a selective S6K1 inhibitor following transection of the cortico-
spinal tract (CST) promoted robust CST axonal regeneration across
and beyond the lesion site. This regeneration was accompanied by
improved behavioral recovery, suggesting that axon regeneration
induced by S6K1 inhibition may be helpful in recovery from CNS
injury.
Materials andMethods
Antibodies, reagents, and compounds. Pan Akt (#2920), pT308Akt (#4056),
pS473Akt (#4058), pan S6 ribosomal protein (#2317), pS240/244S6 (#5364),
pan S6K1 (#2708), and pT389S6K1 (#9205) antibodies (working dilution
1:1000, except for S6 pan, which was diluted 1:300) were purchased from
Cell Signaling Technology. GAPDH (#IMG-5019A-1) antibody (working
dilution 1:500) was purchased from Imgenex. III-tubulin (#T2200) anti-
body (working dilution 1:2000) was purchased from Sigma-Aldrich. Alexa
fluorophore-conjugated secondary antibodies (working dilution 1:1000)
were purchased form Invitrogen. IRDye-700- and IRDye-800-conjugated sec-
ondary antibodies (working dilutions 1:15000) were purchased fromLiCor.
Poly-D-lysine (P7886-500MG) and sterile DMSO (D2650) were purchased
from Sigma-Aldrich. Hippocampal tissue was incubated in Hibernate E
(without calcium) from BrainBits, supplemented with NeuroCult SM1
(05711) from StemCell Technologies. Neurons were cultured inNbActive4
media from BrainBits. Accell siRNAs (working concentration 1 M) were
purchased from GE Healthcare/Dharmacon (scramble SMARTPool #D-
001910-10-20, S6K1 siRNA SMARTPool #E-099323-00-0003, scramble
oligo #D-001910-04-05, S6 set of 4 siRNA oligos #EU-089542-00-0002).
Kinase inhibitors PF-4708671, ML-7, ROCK inhibitor IV, IKK inhib-
itor VII, Flt3 inhibitor III, and Bisindolylmaleimide I, and rapamycin
were purchased from EMD Millipore. GW784684X, GW659386A,
GSK1511931A, GSK269962B, and SB-750140 were acquired via col-
laboration from GlaxoSmithKline. RO0480500-002 was acquired via
collaboration from Roche. VCC379989:02 and VCC781016:01 were
purchased from Vichem. Torin-2 was purchased from Tocris Biosci-
ence. All other reagents were purchased from Invitrogen.
Neurite outgrowth assay for small-molecule kinase inhibitors. The neu-
rite outgrowth assay was performed as previously described (Al-Ali et al.,
2013b), with minor modifications. Briefly, compounds were tested with
rat embryonic (E18) hippocampal neurons cultured at low density for
48 h. Neurons were plated at 1500–1800 cells/well in 96-well plates
coated overnight with poly-D-lysine. For the pretreatment condition,
mTOR inhibitors were added to the cells 1 h before the addition of S6K1
inhibitor. Plates were fixed, immunostained, and imaged in a Cellomics
ArrayScan VTI. Images were automatically traced using the Neuronal
Profiling Bioapplication (version 3.5). Data were analyzed using
MATLAB (R2014b, MathWorks).
Neurite outgrowth assay for siRNAs.Dissociated hippocampal neurons
were seeded in 96-well poly-D-lysine-coated plates at 1500–1800 cells per
well in 150l of NbActive4 and incubated overnight. The following day,
siRNA solutions were prepared in 96-well plates at 2 M in 100 l of
media and allowed to equilibrate for 1 h in aCO2 incubator. Immediately
before treatment, 100 l of media was removed from the cells and re-
placed with 50 l of siRNA solution (duplicate wells for each treatment)
to bring the final siRNA reagent concentration to 1 M (per vendor
recommendation) in a total volume of 100 l. Cells were incubated for
96 h, then fixed and analyzed for neurite outgrowth as previously de-
scribed for the neurite outgrowth assay (Al-Ali et al., 2013b).
Assessing protein phosphorylation. Hippocampal (E18) neurons were
cultured inNbActive4 (Invitrogen). Cells were seeded into 24-well plates
at 0.25–0.5 106 cells/well in 0.5ml ofmedia.Compound stocks (10mM in
DMSO) were diluted in cell culture media at 2 final concentration and
added at 1:1 volume to cells (final volume 1ml). Control wells received
the corresponding volume of DMSO, which was kept constant across all
treatments at 0.2% v/v. Each plate contained two DMSO control wells
(one normalization control and one treatment control). After indicated
time points, cells were washed once with PBS and collected in 120 l of
lysis buffer containing 100 mM Tris-HCl, pH 6.8, 20% glycerol, 4% SDS,
5%-mercaptoethanol, phosphatase inhibitormixture (Clontech), pro-
tease inhibitor mixture (Roche), and 0.2% bromophenol blue. Lysates
were boiled for 5–7 min, and 20 l of each sample was loaded on a 10%
polyacrylamide gel. Protein was transferred from the gel to a nitrocellu-
lose membrane in a wet transfer apparatus using 25 mM sodium bicar-
bonate as transferring solution. Membranes were blocked with Odyssey
blocking buffer for at least 1 h, then incubated overnight in primary
antibody solution (1:1 PBS, Odyssey blocking buffer with 0.1% Tween
20) at 4°C on a shaker. Membranes were washed 3 in PBS-Tween (10
min washes) and incubated in secondary antibody solution (secondary
antibodies in 1:1 PBS, Odyssey blocking buffer with 0.1% Tween and
0.02% SDS) at room temperature for 2 h with shaking. The 800-IR-dye-
conjugated secondary antibodies were used to develop total protein
bands, and the 680-IR-dye-conjugated secondary antibodies were used
to develop phosphorylated protein bands. Finally, membranes were
washed 5 in PBS Tween (10 min washes). Blots were scanned using an
Odyssey system. Relative change in phosphorylation in response to treat-
ment was computed as follows:
Change in phosphorylation

Sample 700 signal
Sample 800 signalcontrol 700 signalcontrol 800 signal (1)
Assessing target protein knockdown. Neurons were plated in 48-well
plates at0.25 106 cells/well and transfected with siRNAs at 1M in a
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total volume of 200l. Three days following transfection, cells were lysed
and analyzed by SDS-PAGE followed by Western blotting as above.
Assessing S6 mRNA knockdown.Neurons were plated in 48-well plates
at0.25 106 cells/well and transfected with siRNAs at 1 M in a total
volumeof 200l. One day following transfection, RNAwas isolated from
theneuronsusing themicroRNAeasy (QIAGEN,#74004)kit. Total amount
of isolated RNA was quantified using a NanoDrop 1000 (NanoDrop Prod-
ucts). Reverse transcription (RT) reaction was performed using the
Advantage RT PCR kit (Clontech) with 1 g of isolated RNA and both
oligo dT and randomhexamer primers. Samples were collected from two
independent experiments and qPCR for each sample was set up in trip-
licates using the Power SYBR Green PCR Master Mix (Applied Biosys-
tems) according to manufacturer suggestions. Controls included a
No-RT control to ensure absence of contaminatingDNA, cDNAplasmid
control (1 pg/ml) to verify the correct product size, and qPCRofGAPDH
and -actin housekeeping genes for normalization. Reactions were run
on 7300 RealTime PCR System (Applied Biosystems), and the results
were analyzed using Sequence Detection System version 1.2.3 (Applied
Biosystems) software.
Animal studies. A total of 30 adult C57BL/6 mice (7 weeks, Harlan
Laboratories) were used in the in vivo studies. Only female mice were
used because males often get bladder infections and develop kidney
problems after this kind of spinal cord injury. All behavior testing, sur-
gical interventions, and postoperative animal care were performed in
accordance with the Guide for the care and use of laboratory animals
(National Research Council) and were approved by the Indiana Univer-
sity Institutional Animal Care and Use Committee. The mice were pre-
trained for behavior analysis for 4 weeks before the surgery (see Fig. 8A).
Two mice were unable to learn the task and were excluded from the
experiment. The remaining 28 animals received dorsal hemisection sur-
gery at the end of the pretraining and baseline behavioral testing.
Spinal cord dorsal hemisection and cortical injection of PF-4708671. At
the 10th week of age (4 weeks after training), mice (20–30 g) were anesthe-
tizedwith an intraperitoneal injection of a ketamine/xylazine/acepromazine
mixture (120 mg/3.3 mg/1.67 mg /kg) provided by Laboratory Animal Re-
source Center at IndianaUniversity School ofMedicine, Indianapolis.Mice
were then subjected to stabilization of the C5/C6 vertebra with a vertebral
stabilizer. After the exposure of the C5-C6 dorsal laminae, a transverse du-
rotomy at the interlaminar space betweenC5 andC6was performed using a
30Gneedle followedbycuttingwithapairofmicroscissors.Amidlinedorsal
hemisection was performed using a VibraKnife attached to the Louisville
Injury System Apparatus (Louisville Impactor System, Louisville, KY) ac-
cording toapreviouslypublishedmethod(Sivasankaranet al., 2004;Y.Liuet
al., 2008; Zhang et al., 2013) with modifications. Briefly, the blade was 1.2
mmwide andwas advanced 0.9mmventrally from the dorsal surface of the
cord, extending beyond the central canal (see Fig. 1B). Such a lesion com-
pletely transected the entire dorsal corticospinal tract (dCST) and lateral
corticospinal tract (lCST) on both sides. In the C57BL/6 mice, we did not
observe the presence of the ventral CST (vCST). Thus, a dorsal hemisection
in our model (1.2 mm wide, 0.9 mm deep) transected all descending CST
axons at the lesion site. In this case, any labeled CST axons growing beyond
the lesion would be interpreted as coming from cut axons via either regen-
eration from the tips or by regenerative sprouting.
Compounds were injected bilaterally into sensorimotor cortex after
the C5-C6 dorsal hemisection according to a previously established
method (Wang et al., 2014). Briefly, after the dorsal hemisection, animals
were randomly assigned into four groups that receive the following cor-
tical injections (n 7/group): Group 1 (control): DMSO (0.1% DMSO
in 0.1 MPBS); Group 2 (low-dose PF): 1mMPF-4708671 (in 0.1%DMSO
in 0.1 M PBS); Group 3 (medium-dose PF-4708671): 5 mM PF-4708671
(in 0.1% DMSO in 0.1 M PBS); and Group 4 (high-dose): 10 mM PF-
4708671 (in 0.1% DMSO in 0.1 M PBS). Five stereotaxic injections of
PF-4708671 were made into the sensorimotor cortex on each side at a
depth of 0.5 mm and coordination of 2 mm/1.5 mm, 1.25 mm/1.5 mm,
0.5mm/1.5mm,0.25mm/1mm, and1mm/1mm(anteroposterior/
mediolateral to the bregma)with 1l/injection site. After the surgery and
PF-4708671 injections, an analgesic agent, buprenorphine, was given
intraperitoneally every 12 h for 2 d (Laboratory Animal Resource Center,
Indiana University, Indianapolis).
Single-pellet reaching task. The single-pellet reaching task is a simple
repetitive training protocol used to test the precise and coordinated mo-
tor movements of the forelimb. The single-pellet reaching task was per-
formed in accordance with a previously described method (Chen et al.,
2014). In this test, a clear Plexiglas training chamber (15 cm long 8.5
cm wide 20 cm tall) contains three vertical slits (one slit on “shaping”
edge and two slits on the opposite “training” edge). The vertical slits are
0.5 cmwide and 13 cm tall and are located on the front wall of the box: in
the center, on the left side, and on the right side. A food platform (8.5 cm
long 4.4 cm wide 0.9 cm tall) is placed in the front side (facing the
trainer) of the training chamber during training sessions. There are two
divot slots on the food platform for positioning seeds: one slot on the left
and the other slot on the right side. The divots are 0.3 cm from the long
edge and 2.4 cm from the width edge (Chen et al., 2014). The left and
right divot slots correspond to the left and right slits in themouse training
chamber and are used for training of dominant forelimbs. The purpose of
having these divot slots is to ensure that the pellet (millet seed) is placed
consistently at the same place for each reaching attempt. The training
phase contained food deprivation (2 d), shaping (7 d), and training (9 d).
Themice were trained for 30 reaching attempts on the preferred limb for
20 min per day. Reaching behavior and scoring were recorded according
to the following four categories: (1) Success: The mouse reaches with
preferred paw, grasps and retrieves the seed, and feeds it into its mouth.
Success (%) (the number of success/total number of feeding seeds)
100. (2) Grasp: The mouse reaches with preferred paw, grasps the seed,
but drops it before putting it into itsmouth. Grasp (%) (the number of
grasp/total number of feeding seeds) 100. (3) Reach: The mouse reaches
with preferred paw toward the seed, but it eithermisses the seed or knocks it
off from the holding plate. Reach (%) (the number of reach/total number
of feeding seeds) 100. (4)No reach:Themouse attempts to grasp the seed,
but it cannot reach the seed in the holding plate. No reach (%)  (the
number of no reach/total number of feeding seeds)  100. In all mice, a
baseline taskwasperformedat3dbefore the surgery.Thesingle-pellet reach-
ing task was also assessed at 1, 2, 4, and 6 weeks after the dorsal hemisection
and PF-4708671 treatment (see Fig. 8A).
Rotarod test.TheRotarod testwas used to assessmotor coordination in
rodents following procedures described previously with minor modifi-
cation (N. K. Liu et al., 2013). Briefly, mice were placed on a rotating rod
(diameter 30 mm) in a 5-lane Rotarod device (IITC Life Science) that
accelerated from 0 to 30 rpm within a 90 s period, with each trial lasting
a maximum of 120 s. Trials ended when the animal either fell off the rod
or clung to the rod as it made one complete rotation. The animals were
trained five times per day for 3 d. The Rotarod tests were performed
before injury to score the baseline latencies for each animal. The baseline
value was scored as the mean of five trials at 3 d before surgery (see Fig.
1A). The Rotarod test was performed at 1, 2, 4, and 6 weeks after the
surgery. Data were expressed as the ratio of duration relative to baseline.
Adhesive removal test. Animals were trained for the adhesive removal
test for 3 d, and the baseline was recorded at 3 d before the dorsal he-
misection (see Fig. 8A) according to a protocol previously described
(Bouet et al., 2009; N. K. Liu et al., 2013). This concise sensorimotor
function assay was performed by applying adhesive tape on the forepaw
of the animal andmeasuring the time to contact and the time to remove it. A 3
mm 4 mm adhesive tape strip (waterproof adhesive tape, ACME/Chaston)
was, respectively, pressed on the left and right sides of the forepaw covering
thewhole palmandproximal part of the digits. The time to contact and time
to remove the adhesive tape were collected with a maximum of 3 min/
animal. The time to contact is defined as the point atwhich themouse reacts
to theaffectedpawbyeither shaking itspaworbringing thepawto itsmouth.
The time to remove is the point when the tape is removed by its mouth,
combined with assistance from the forelimb in loosening it. The adhesive
removal testwas also assessed at 1, 2, 4, and 6weeks after the dorsal hemisec-
tion (see Fig. 8A).
Grid-walking test. The grid-walking test assesses the ability to place the
forepaws on the rungs of a grid accurately during spontaneous explora-
tion. The mice were trained to walk on a wire grid (0.35 m long with 10
mm squares) for 3 d according to an established protocol with modifica-
tions (N. K. Liu et al., 2013). The percentage of forepaw drops below the
grid plane during a 3min observation period was calculated at 3 d before
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surgery (as a baseline) and at 1, 2, 4, and 6weeks after the dorsal hemisec-
tion (see Fig. 8A).
Anterograde tracing with biotinylated-dextran amine. Six weeks after
the dorsal hemisection,mice received bilateral injections of biotinylated-
dextran amine (BDA, 10,000 MW, 10% in saline; Invitrogen) into the
sensorimotor cortex to trace the CST axons anterogradely. Five injec-
tions of BDA (0.5 l/each) were made into the sensorimotor cortex on
each side using the same coordinates as the PF-4708671 injection. For
each injection, 0.5 l of BDA was delivered for a period of 5 min via a glass
pipette attached to a 10 l syringe connected to the Stoelting motorized
integrated stereotaxic injectors system (Stoelting). Mice were humanely
killed by a lethal dose of anesthesia and transcardially perfused with saline
followed by 4% PFA 2 weeks after the BDA injection (see Fig. 1A).
BDA visualization and immunofluorescent labeling.After perfusion, the
spinal cords containing the lesion epicenter were removed and postfixed
in 4% PFA overnight, and were then equilibrated in 30% sucrose for
cryoprotection. Sagittal sections at 25 m were cut using a cryostat.
BDA-labeled CST axons were visualized by using avidin-biotin peroxi-
dase incubation followed by biotinyl tyramide and Extra-Avidin-FITC
(SAT700, PerkinElmer) (Wang et al., 2014). Lesion gaps were identified
in the same sections by immunostaining for GFAP (1:1000; Millipore).
Quantification of BDA-labeled CST axons was performed with the ex-
perimenter blind to the treatment groups. Briefly, 7 sagittal sections of
the spinal cord spaced 125mapartwere chosen. Themiddle sectionwas
defined as the one that cut through the central canal (see Fig. 3A). The
other 6 sections were selected at 125, 250, and 375 m lateral to the
middle section on each side. The number of BDA-immunoreactive (IR)
CST axon fragments was counted at defined zones spaced 0.5 mm apart.
The axon numbers were converted into CST Axon Index defined as a
ratio of the BDA-IR axon number at a given zone over the total number
of BDA-IR axons in the dCST on a cross section of the C1 spinal cord.
The lesion epicenter on the sagittal section is defined as “0 mm,” and all
other zones are defined as their distances from the lesion epicenter.
Statistical and computational analyses. All computational analyses
and tools were implemented in MATLAB (R2013b and R2014b,
MathWorks). Statistical analyses were performed in GraphPad Prism
(5.03), MATLAB, or Excel (2007). Data were presented as mean SEM,
unless otherwise noted. Statistical analyses were performed using the
GraphPad Software (Prism 5.0) with ANOVA followed by the appropri-
ate post-test correction, or two-way repeated-measures ANOVA with
Bonferroni post-test. Statistical significance was accepted with p	 0.05.
Results
Phosphorylation of ribosomal S6 protein is reduced by kinase
inhibitors that promote neurite outgrowth
A set of small-molecule kinase inhibitors was selected from the
hits in our phenotypic screen to represent a variety of chemical
scaffolds, distinct kinase inhibition profiles, and potentially di-
versemechanisms for promoting neurite outgrowth (Al-Ali et al.,
2013b, 2015). In the present study, we investigated the effect of
these representative compounds on S6 phosphorylation, in pri-
mary hippocampal neurons. We observed that the majority (9 of
14) of these compounds induced a significant reduction in S6
phosphorylation at S240/244 (Fig. 1A), sites phosphorylated exclu-
sively by S6K1/2 (Pende et al., 2004). Interestingly, only 4 of the
14 compounds directly inhibit S6 kinase activity in enzymatic
assays in vitro (Fig. 1B). This finding suggests that some of the
compounds reduce S6K1 phosphorylation of S6 without directly
inhibiting the enzyme.
Highly selective S6K1 inhibitor promotes neurite outgrowth
Because the catalytic kinase domains of S6 kinases are structurally
similar, most inhibitors of one S6 kinase tend to inhibit other
kinases within the S6 kinase family (Fig. 1B). One compound
(PF-4708671), however, has unusual selectivity for S6K1, both
within the groupof S6 kinases (Pearce et al., 2010a) and across the
kinome (Fig. 2A). PF-4708671 was shown to inhibit S6K1 with
Figure 1. Ribosomal S6 protein phosphorylation is reduced by most kinase inhibitors that promote neurite outgrowth in primary hippocampal neurons. A, Fourteen small-molecule kinase
inhibitorswere selected, froma set of neurite outgrowth-promoting compounds, to represent distinct chemical scaffolds anddiverse kinase activity profiles (Al-Ali et al., 2015).Neuronswere treated
with the compounds at 1M (or DMSO vehicle as a control) for 10 h before lysis and analysis by Western blotting. Most compounds (9 of 14) resulted in significantly reduced S6 phosphorylation
(relative to DMSO control) at Serine 240/244, the substrate site for S6K1, and four others exhibited a trend toward reduced S6 phosphorylation. Data aremean SEM. n 4 experimental replicates
from two separate preparations of primary neurons. *p	 0.05 (one-way ANOVA with Dunnett’s multiple comparisons test). **p	 0.01 (one-way ANOVA with Dunnett’s multiple comparisons
test). ***p	 0.001 (one-way ANOVA with Dunnett’s multiple comparisons test). B, In vitro kinase activity assays for RSK1 (RPS6KA1), RSK3 (RPS6KA2), RSK2 (RPS6KA3), MSK1 (RPS6KA5), MSK2
(RPS6KA4), RSK4 (RPS6KA6), and S6K1 (RPS6KB1) with the 14 representative compounds. Increasing inhibition is indicated by increased intensity of yellow. Only four of the compounds directly
inhibited catalytic activity of S6 kinases in vitro (red arrowheads).
7082 • J. Neurosci., July 26, 2017 • 37(30):7079–7095 Al-Ali et al. • Inhibiting S6 Kinase 1 Promotes Axon Regeneration
Figure 2. A selective S6K1 inhibitor promotes neurite outgrowth in primary hippocampal neurons. A, in vitro kinase inhibition profiling of PF-4708671 with a panel of 200 kinases (Al-Ali et al.,
2015) shows activity against S6K1 and its isoform S6K2, and little to no activity against other kinases, including othermembers of the RPS6K family of kinases.B, Hippocampal neurons treatedwith
10M PF-4708671 for 48 h (right) show longer neurites than those treated with vehicle (left). Green represents III-tubulin immunostaining. Blue represents nuclear stain. Scale bar, 50m.
C, Western blot of cell lysates from neurons treated for 1 h with PF-4708671 at the indicated concentrations. D, Red circles represent quantification of NTL of neurons treated with PF-4708671
expressed as percentage of DMSO controls. Neurons were treated at the indicated concentrations for 48 h. Data are mean SEM. n 3 separate preparations of hippocampal neurons with three
experimental replicates for each. Blue squares represent quantification of phospho S6 to pan S6 levels in C expressed as percentage of DMSO control. Data are mean SEM. E, Western blot of cell
lysates from neurons treated for the indicated times with DMSO or 10 M PF-4708671. F, Blue squares represent quantification of phospho- to pan-S6 band intensities in E and expressed as
percentage of DMSO control. Data are mean SEM. n 3 experimental replicates from a single preparation of primary neurons.
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400-fold selectivity over S6K2 (IC50 0.16
M vs 65 M) and5–60-fold selectivity
over RSKs and MSKs. Treating cells with
10 M PF-4708671 strongly inhibits S6K1
activity with no detectable inhibition of
RSKs or MSKs, suggesting that intracellu-
lar S6K1 is selectively inhibited at or
belowthat treatment concentration (Pearce et
al., 2010a).We treated primary hippocam-
pal neurons with PF-4708671 and found
that it induced a large increase in neurite
outgrowth relative to DMSO (vehicle)
controls, reaching 200% at 10 M (Fig.
2B). Western blot analysis of lysates from
neurons treated for 1 h with PF-4708671
showed a dose-dependent decrease in
S240/244S6 phosphorylation (Fig. 2C,D),
which was correlated with induction of
neurite outgrowth (Fig. 2D).With contin-
uous PF-4708671 treatment, S6 phos-
phorylation remained strongly inhibited
for the full duration of the neurite out-
growth assay (Fig. 2E,F).
SiRNA-mediated knockdown of S6K1
promotes neurite outgrowth
We sought an independent line of evi-
dence that the correlation between S6K1
inhibition and neurite outgrowth can be
attributed to S6K1 itself, rather than to
pharmacological linkage within the S6 ki-
nase family or another “off target” effect.
We previously determined that Accell siR-
NAs can be used for efficient protein knockdown in cultured
hippocampal neurons (Al-Ali et al., 2015). We therefore used
Accell siRNAs directed against S6K1 (-S6K1 siRNA) and found
that, by 2 d following transfection, S6K1 protein abundance was
reduced by 60% (Fig. 3A,B). As expected, this was accompa-
nied by a decrease in S6 phosphorylation at S240/244 (Fig. 3A,C).
To investigate the effect of S6K1 knockdown on neurite out-
growth, we treated neurons with -S6K1 siRNA using the same
format as the compound screening assay with twomodifications:
(1) the number of replicates per condition was increased from 2
to 6 to account for variations inherent to siRNA knockdown
experiments; and (2) assay duration was increased from 2 to 5 d
to allow time for protein knockdown to take effect. Consistent
with the previous inhibitor data, S6K1 knockdown led to a sig-
nificant increase in neurite total length (NTL) compared with
controls (Fig. 3D).
Inhibiting S6K1 in primary neurons induces PI3K signaling
and stimulates mTOR activity
Studies in non-neuronal cells have shown that S6K1 inhibits
PI3K activity, thus serving as a negative feedback regulator of the
PI3K/mTOR pathway (Zoncu et al., 2011; Shimobayashi and
Hall, 2014). We therefore investigated the effect of S6K1 inhibi-
tion on PI3K/mTOR signaling in neurons. PI3K is recruited to
the plasma membrane by a variety of transmembrane receptors
(e.g., insulin or growth factor receptors),where it catalyzes thephos-
phorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) into
phosphatidylinositol-3,4,5-trisphosphate (PIP3) (VivancoandSaw-
yers, 2002). PIP3 recruits and activates kinases like PDK1 and Akt
through pleckstrin homology domains, allowing PDK1 to phos-
phorylate andactivateAkt atT308 (Sarbassov et al., 2005). PDK1also
phosphorylates S6K1 at T229; however, this step occurs indepen-
dently of PIP3 and is therefore not directly regulated by PI3K (Mora
et al., 2004). Activated Akt leads to activation of mTOR complex 1
(mTORC1), composed of mTOR and its binding partner Raptor
(Zoncu et al., 2011).mTORC1phosphorylates S6K1atT389, leading
to its activation (Q. Liu et al., 2010, 2011). In addition tomTORC1,
mTOR forms a second complex with Rictor, mTOR complex 2
(mTORC2)(Sarbassovet al., 2004).PI3Kactivity (andPIP3produc-
tion) stimulates mTORC2, which phosphorylates Akt at S473 and
facilitates its activation by PDK1 (Sarbassov et al., 2005). PTEN, a
dual-specificity protein/lipid phosphatase, silences this pathway by
hydrolyzing PIP3 into PIP2 (Song et al., 2012).
Treating hippocampal neurons with 10 M PF-4708671 rap-
idly inhibited S6K1 activity (S6 phosphorylation at S240/244; Fig.
4A,B, blue line). A simultaneous increase was observed in
mTORC1 activity (phosphorylation of S6K1 at T389) (Fig. 4A,C).
Additionally, PF-4708671 treatment increased activities of PDK1
(Akt phosphorylation at its T308) and mTORC2 (Akt phosphor-
ylation at its S473) (Fig. 4A,D,E). In agreement with previous
work showing that PDK1 phosphorylation of S6K1 is indepen-
dent of PI3K (Mora et al., 2004), we did not observe a strong
increase in S6K1 T229 phosphorylation (Fig. 4A). These results
demonstrate that inhibiting S6K1 in neurons induces the PI3K
pathway and leads to the activation of both mTOR complexes.
Inhibiting both mTOR complexes abolishes PF-4708671’s
effect on neurite outgrowth
To investigate whether mTOR activity is required for neurite out-
growth promotion by PF-4708671, we used two mTOR inhibitors:
Figure 3. siRNA-mediated knockdown of S6K1 promotes neurite outgrowth in primary hippocampal neurons. A, Western blot
of cell lysates (3 d after transfection) from neurons transfected with S6K1-targeting or scrambled siRNAs. B, C, Quantification of
A expressed as percentage of scramble control. Data are mean SD. D, Quantification of NTL in neurons transfected for 5 d with
-S6K1 siRNA or scrambled control. Data are mean SEM. n 6 experimental replicates from a single preparation of primary
neurons. **p	 0.01 (Student’s t test, one-tailed). ***p	 0.001 (Student’s t test, one-tailed).
7084 • J. Neurosci., July 26, 2017 • 37(30):7079–7095 Al-Ali et al. • Inhibiting S6 Kinase 1 Promotes Axon Regeneration
rapamycin and Torin-2. Rapamycin is an allosteric, selective, and
specific competitive inhibitor of the mTORC1 (Feldman et al.,
2009). Torin-2, on the other hand, is an ATP-competitive inhibitor
of mTOR kinase, and therefore inhibits both mTORC1 and
mTORC2 (Q. Liu et al., 2011). Treating neurons with either rapa-
mycin (10 nM) or Torin-2 (10 nM) inhibited mTORC1, which in
turn inhibited S6K1 activity (Fig. 4A–C). Whereas rapamycin did
not inhibit mTORC2, Torin-2 inhibited it as expected (Fig. 4A,E).
Torin-2 also decreased phosphorylation of Akt at T308, which is
likely due to the dependence of PDK1 activity at this site on prior
phosphorylation at S473 (mTORC2’s target site) (Hart and Vogt,
2011).
Treating neurons with either mTOR inhibitor completely in-
hibited mTORC1 activity, with Torin-2 additionally inhibiting
Figure 4. PF-4708671 induces PI3K signaling and stimulates mTORC1 and mTORC2 activities in primary hippocampal neurons. A, Western blot of cell lysates from neurons treated with
PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. B–E, Quantification of band intensities in A expressed as percentage of DMSO controls (dashed lines).
Data are mean SEM. n 3 experimental replicates from three separate preparations of primary neurons.
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Figure 5. Treatment with mTOR inhibitors counteracts mTORC1 and mTORC2 induction by PF-4708671. A, Western blot of cell lysates from neurons treated with DMSO or PF-4708671,
PF-4708671plus rapamycin (cotreated), PF-4708671plus Torin-2 (cotreated), rapamycin thenPF-4708671 (pretreated), or Torin-2 thenPF-4708671 (pretreated) at the indicated concentrations for
1h.B,C, Quantificationof band intensities inAexpressedaspercentageofDMSOcontrols (dashed lines). Data aremeanSD.n2or 3experimental replicates fromasinglepreparationof primary
neurons.
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mTORC2 activity (Fig. 4A,C). Treating neurons with PF-
4708671 together with either mTOR inhibitor prevented the PF-
4708671-induced spike in mTORC1 activity (PF-4708671 alone
vs PF-4708671 
 rapamycin); however, PF-4708671 delayed
rapamycin’s ability to inhibit mTORC1 activity (PF-4708671 

rapamycin vs rapamycin alone) (Fig. 4A,C). This suggests that
the rapid activation of mTORC1 induced by PF-4708671 coun-
teracts pharmacological inhibition of mTORC1. Thus, to ensure
complete inhibition of mTOR during treatment with PF-
4708671, we (1) pretreated neurons with the mTOR inhibitors
for 1 h before the treatment with PF-4708671 or (2) cotreated
with the mTOR inhibitors at a higher concentration (100 nM).
Pretreating neurons with 10 nM rapamycin kept mTORC1 activ-
ity below control levels even after addition of PF-4708671 (Fig.
5A,B). Both pretreating and cotreating neurons with 100 nM
rapamycin resulted in strong inhibition ofmTORC1 that was not
counteracted by PF-4708671 (Fig. 5A,B).Neither pretreating nor
cotreating neurons with 10 nM Torin-2 inhibited mTORC1 ac-
tivity below DMSO control levels after addition of PF-4708671
(Fig. 5A,C). With 100 nM Torin-2, however, either pretreatment
or cotreatment resulted in complete inhibition of mTORC1 and
mTORC2, which was not counteracted by PF-4708671 (Fig.
5A,C). In neurons, therefore, treatment with 100 nM Torin-2
appears to be sufficient for fully inhibiting mTORC1 and
mTORC2, and preventing PF-4708671 from countering this
inhibition.
We tested the effects of the various treatments in the neurite
outgrowth assay. We found that PF-4708671’s ability to induce
neurite outgrowth was partially lost in conditions where strong
inhibition of mTORC1 activity was maintained (pretreatment
with 10 nM rapamycin, pretreatment or cotreatment with 100 nM
rapamycin; Fig. 6A). In conditions where both mTORC1 and
mTORC2 were strongly inhibited (pretreatment with 10 nM
Torin-2, cotreatment with 100 nM Torin-2), PF-4708671’s effect
on neurite outgrowth was completely abolished (Fig. 6B). These
results suggest that mTOR activity is required for connecting the
induction in PI3K signaling to the increase in neurite outgrowth,
and suggest that mTORC2 has a previously unappreciated role in
this process.
Knockdown of S6 protein promotes neurite outgrowth
Dysregulation of S6 phosphorylation is associated with a number
of nervous systemdisorders (Biever et al., 2015). Given the strong
correlation between decreased S6 phosphorylation and increased
neurite outgrowth in our cells, we sought to explore whether
lowering overall levels of S6 can in itself influence neurite out-
growth.We transfected cells with four different siRNAs targeting
S6, and compared their effects on both S6 expression and neurite
outgrowth. Three of the four S6 targeting oligos showed amarked
decrease in S6 mRNA by 24 h following transfection (Fig. 7A).
The decrease in S6 mRNA levels was correlated with a significant
increase in neurite outgrowth in neurons (Fig. 7B,C), suggesting
that decreases in S6 levels (and consequently in levels of phos-
phorylated S6) are causally associated with promotion of neurite
growth. Conversely, neither wild-type S6 nor a phosphorylation-
deficient S6 mutant (Ser235,236,240,244,247 ¡ Ala) altered neurite
outgrowth when overexpressed in the neurons (data not shown).
These data suggest that pS6 levels in the cultured neurons are
Figure 6. Inhibiting both mTORC1 and mTORC2 abolishes neurite outgrowth promotion by PF-4708671. A, Rapamycin treatment; B, Torin-2 treatment. Quantification of NTL from neurons
treated with PF-4708671 alone, rapamycin or Torin2 alone, pretreated with rapamycin or Torin-2 before treatment with PF-4708671, or cotreated with rapamycin or Torin-2 in combination with
PF-4708671, expressed as percentage of DMSO controls (dashed lines). Data are mean SEM. n 15 technical replicates. *p	 0.05, treatment versus DMSO control (one-way ANOVA with
Dunnett’s multiple comparisons test). **p	 0.01, treatment versus DMSO control (one-way ANOVA with Dunnett’s multiple comparisons test). ***p	 0.001, treatment versus DMSO control
(one-way ANOVA with Dunnett’s multiple comparisons test). ##p 	 0.01 (one-way ANOVA with Tukey’s multiple comparisons test). ###p 	 0.001 (one-way ANOVA with Tukey’s multiple
comparisons test).
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already at saturating levels, and overexpression sufficient for a
dominant negative phenotype is difficult to achieve.
Selective S6K1 inhibitor promotes regeneration of the CST
To assess the effect of S6K1 inhibition on CST axonal regenera-
tion in vivo, we injected PF-4708671 bilaterally into sensorimotor
cortex (the origin of the CST) immediately after a C5/C6 dorsal
spinal cord hemisection (DH) in adult mice (Fig. 8). The com-
pound was injected at three different concentrations: 1, 5, and 10
mM,with 10l total volume injected per animal. The anterograde
tracer BDA was injected bilaterally into sensorimotor cortex 6
weeks after the surgery, and 7 sagittal/parasagittal sections of the
spinal cord spaced 125 m apart were analyzed (Fig. 9A). The
middle sectionwas defined as the one that cut through the central
canal. The other 6 sections were selected at 125, 250, and 375m
lateral to the middle section on each side. Figure 9C–F shows
BDA (axons) and GFAP (astrocytes) double immunostaining in
the representative sagittal sections in the highest PF-4708671
dose group. A narrow and delicate lesion gap through the dorsal
half of the cord was clearly seen at 8 weeks after DH, ensuring the
completeness of the transection of both the dorsal and lateral CST
(Fig. 9B–D). We found that the highest dose of PF-4708671 pro-
moted considerable regeneration of the BDA-labeled CST axons
through and beyond the lesion gap for relatively long distances
(6 mm) (Fig. 9C–G). In cross sections of the spinal cord 6–9
mm caudal to the lesion, no labeled CST fibers in the positions of
the dorsal and lateral CSTs could be observed (Fig. 9B), confirm-
ing that both CST projections were completely transected at the
lesion site. Importantly, some regenerating CST axons were seen
in the gray matter of the spinal cord in these sections, indicating
that regenerated CST axons extend for a distance of at least 9mm
beyond the site of dorsal hemisection (Fig. 9B). Regeneration of
theCST into the distal host spinal cord can be further appreciated
by Neurolucida reconstruction (Fig. 9G) of a single section
shown in Figure 9F. High magnification of the lesion area, boxed
in Figure 9C–F, shows clearly the lesion gap surrounded by reac-
tive astrocytes (Fig. 9C1–F1, GFAP, red). Axonal regeneration
through the lesion and beyond could be appreciated in these
high-magnification images (Fig. 9C1–F1, blue arrows). Regener-
ated axons, after penetrating the lesion gap, grew longitudinally
within the gray matter, indicating that the gray matter is more
permissive for CST growth than the white matter in this
paradigm.
Using BDA andGFAP double immunostaining, we compared
regeneration of the CST axons among different groups (Fig. 10).
In the DMSO control group, BDA-labeled CST axons stopped at
the lesion borderwith few, if any, axons across the lesion gap (Fig.
10; DMSO control). In each PF-4708671 treatment group, nu-
merous BDA-labeled CST axons were found to regenerate
through and beyond the lesion gap and elongate within the gray
matter of the distal host spinal cord for considerable distances.
Axonal regeneration through the lesion gap in PF-4708671-
treated groups could be further appreciated in representative
high-magnification images (Fig. 10). Quantification of BDA-
labeled CST axons showed that PF-4708671 treatment signifi-
cantly enhanced CST axonal regeneration compared with the
DMSO control (Fig. 10, bottom histogram). The highest dose of
PF-4708671 promoted significantlymore CST axon regeneration
into the 0–0.5 mm zone than the other PF-4708671 doses.
Selective S6K1 inhibitor enhances functional recovery of mice
after dorsal hemisection of the cervical spinal cord
Multiple behavioral tests were used to assess forelimb functional
recovery after dorsal hemisection of C5/C6 spinal cord: Rotarod,
grid-walking, adhesive removal, and single pellet tests. The Ro-
tarod test evaluates forelimb and hindlimb motor coordination
and balance. The preinjury baseline test showed no statistically
significant differences among starting groups, and the average
time on the Rotarod was 81.36 s. The time on the Rotarod re-
markably decreased after surgery. At 1 week after surgery, Ro-
tarod performance was significantly better in all groups receiving
PF-4708671 compared with the control group (Fig. 11A; p 	
Figure 7. Ribosomal S6 protein knockdown induced neurite outgrowth.A, qPCR quantification of S6mRNA in neurons treated (24 h)with four different S6-targeting siRNAs or scrambled control
(Accell siRNA oligos).-S6 siRNAs 2–4 significantly reduced S6 mRNA levels. B, C, Quantification of NTL and length of the longest neurite (LOLN) in neurons transfected for 5 d with-S6 siRNA,
expressed as percentage relative to scrambled control (dashed line).-S6 siRNAs 2–4 significantly increased LOLN, and-S6 siRNAs 2–3 significantly increased NTL. Data are mean SEM. n
4 experimental replicates from a single preparation of primary neurons. *p	 0.05 (one-way ANOVA with Dunnett’s multiple comparisons test). **p	 0.01 (one-way ANOVA with Dunnett’s
multiple comparisons test). ***p	 0.001 (one-way ANOVA with Dunnett’s multiple comparisons test).
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0.01). At 2 weeks after surgery, time on the Rotarod was signifi-
cantly increased in the 1mM (p	 0.01), 5mM (p	 0.001), and 10
mM PF-4708671 (p	 0.001) groups compared with the control
group. At 4 weeks and 6 weeks after surgery, only the 10 mM
PF-4708671 treatment group showed significantly longer time on
the Rotarod compared with the control group (p 	 0.01). Al-
though there were no statistically significant differences among
the three PF-4708671 treatment groups, time on the Rotarod
showed a dose-dependent trend. These data suggest that PF-
4708671 treatment can improve the forelimb and hindlimb mo-
tor coordination and balance of injured mice.
The grid-walking test examines the animal’s motor, sensory,
and proprioceptive abilities to place the front paws on the rungs
of a grid during spontaneous exploration. Before dorsal hemisec-
tion, mice walked on the grid with99.74% accuracy (forelimb
dropped below the grid plane 0.26%). At all observed time points
after surgery, the percentage of forelimb drops dramatically in-
creased in all groups compared with the preinjury baseline, espe-
cially at 3 d after surgery. There were no statistically significant
differences among groups at 3 d or 1 week after surgery (Fig.
11B). At 2 weeks after surgery, however, all three PF-4708671
groups showed significantly improved forelimb grid-walking
function compared with the control group (p 	 0.001). At 4
weeks after surgery, the percentage of forelimb drops was signif-
icantly decreased in both the 5 mM (p 	 0.05) and 10 mM (p 	
0.01) PF-4708671 groups. At 6 weeks after surgery, the percent-
age of forelimb drops in the 10 mM PF-4708671 group was still
significantly lower than the control group (p 	 0.05). These re-
sults indicate that PF-4708671 treatment improves long-term
motor, sensory, and proprioceptive abilities after a cervical dorsal
hemisection.
The adhesive removal test (Bouet et al., 2009) was used to
examine paw and mouth sensitivity (contact time) and dexterity
(removal time). At observed time points after surgery, the contact
time and removal time in each group were longer than preinjury
baselines (Fig. 11C,D). At 1, 2, and 4 weeks after surgery, both
Figure 8. Experimental design of in vivo injurymodel and compound injection.A, Schematic drawing of the timeline, procedures, and behavior assessments.B, Schematic drawing of the tracing
of dorsal (purple) and lateral (green) CST from themotor cortex down to the spinal cord. A dorsal hemisectionwasmade at the C5/C6 level that completely transected both the dorsal and lateral CST.
In this lesion model, the dorsolateral portion of the lateral funiculus remained intact to facilitate animal survival after the cervical injury. Regeneration of CST axons (red) caudal to the injury were
examined up to 9mm from the lesion site. C,D, After PF-4708671 and BDA injections at two different time points, a coronal section of the brain shows an injection site with BDA labeling (C, arrow).
Neuronal nuclei (NeuN) staining of the layer Vmotoneurons showed that the NeuN
motoneurons remained intact at the injection site (D). GFAP staining shows that the injections did not trigger
strong astrocytic glial responses (arrow) at the site of PF-4708671/BDA injections (E). These observations can be further appreciated in a merged image (F ).
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contact time and removal time were sig-
nificantly shorter in PF-4708671 groups
than the control group (Fig. 11C,D), but
there were no significant differences
among three PF-4708671 groups. At 6
weeks after surgery, a significantly shorter
contact time was observed in the 5 and 10
mM PF-4708671 groups (Fig. 11C; p 	
0.05) compared with controls, and a sig-
nificantly shorter removal time was ob-
served in the 10 mM PF-4708671 group
compared with the control group (Fig.
11D; p	 0.05).
The single-pellet reaching task is a sim-
ple repetitive training protocol used to
test the precise and coordinated motor
movements of the forelimb. Before sur-
gery, all animals displayed similar daily
success rates of pellet retrieval (47.02 
1.74%; Fig. 11E). Postoperatively, the suc-
cess rates of mice in all groups was signif-
icantly impaired compared with baseline
of preinjury. PF-4708671-treated mice
showed significant improvement in suc-
cess rates compared with the control
group at 4 and 6 weeks following injury
(Fig. 11E). Notably, the success rates of
mice in the 10mMPF-4708671 was signif-
icantly higher than the 1 mM PF-4708671
group at 6weeks after injury (Fig. 11E; p	
0.01). The reach rates in this task were sig-
nificantly improved in the PF-4708671-
treated groups compared with the control
group at 1, 2, and 6 weeks after injury
(Fig. 11F). Grasp rates were significantly
higher than control in the 5 and 10 mM
PF-4708671 group, but only at 1 week fol-
lowing injury (Fig. 11G; p	 0.05). Failed
reach rates in each of the PF-4708671
groups were significantly lower than the
control group at 1, 2, and 6 weeks after
injury (Fig. 11H). Thus, treatment of the
neurons of origin of the CST with PF-
4708671 improved behavioral recovery
after cervical DH in a dose-dependent
manner in a variety of sensorimotor tasks.
Figure 9. PF-4708671 promoted robust axonal regeneration of the CST through and beyond the dorsal hemisection. A, A cross
section of the cervical spinal cord shows bilateral distribution of BDA-labeled main CST tracts (both dorsal and lateral) and their
sprouting into the spinal gray matter. Red lines indicate sagittal/parasagittal sections spaced 125m apart. B, A cross section of
caudal spinal cord segment 9 mm distal to the injury shows a lack of BDA labeling in the dorsal and lateral CSTs, indicating that
these tracts were completely transected at C5/C6. Some regenerated CST axons were found in the gray matter of the spinal cord
(arrows), indicating that these axons extended for a distance of up to 9mmbeyond the injury site. C–F, Parasagittal sections of the
spinal cord, 125 m apart, from the same animal that received 10 mM PF-4708671 show CST axonal regeneration across and
4
beyond the lesion gap. The regenerated axons elongated
within the distal spinal gray matter for considerable distances
(blue arrows). G, Neurolucida reconstruction of the single sec-
tion from F shows the lesion gap far beyond the main dorsal
CST (between two arrows). Varicosities of regenerated CST ax-
ons extended within the distal spinal gray matter for consid-
erable distances. C1–F1, High magnification of the lesion
area, boxed in C–F, clearly shows the lesion gap (dashed line)
surrounded by relatively mild astroglial responses (GFAP-IR,
red, zigzag arrows). Axonal regeneration through the narrow
lesion gap and beyond could be clearly seen (blue arrows).
Notably, the Vibraknife cut produced a complete and deep
dorsal hemisection, ensuring the transection of all CST ax-
ons at this level. Scale bars: A, B, 200 m; C–F, 400 m;
C1–F1, 100m.
7090 • J. Neurosci., July 26, 2017 • 37(30):7079–7095 Al-Ali et al. • Inhibiting S6 Kinase 1 Promotes Axon Regeneration
Discussion
Knockdown or genetic deletion of PTEN
promotes substantial axon regeneration
in an mTOR-dependent manner, both in
the optic nerve and in the CST (Park et al.,
2008, 2010; K. Liu et al., 2010; Zukor et al.,
2013; Du et al., 2015). It has therefore
been suggested that the activity of S6K1,
an effector of mTOR, is required for re-
generation in this paradigm (Yang et al.,
2014). Nevertheless, experimental results
on this point are conflicting (Hubert et al.,
2014; Yang et al., 2014). In our study, we
found that decreased phosphorylation of
S6K1’s substrate, S6, strongly correlates
with promotion of neurite outgrowth in
primary neurons treated with a variety of
small-molecule kinase inhibitors, and
that pharmacological inhibition of S6K1
promotes neurite outgrowth in primary
neurons. Activation of PI3K/mTOR sig-
naling, in response to the release of
S6K1-mediated negative feedback on this
pathway, may be driving the induction of
neurite outgrowth. Consistent with this,
we observed that inhibiting S6K1 in neu-
rons induced a rapid increase in PI3K sig-
naling and led to the induction of both
mTORC1 and mTORC2 activities.
Previous studies on S6K1’s role in axon
growth/regeneration have led to conflict-
ing conclusions. It is plausible that this is
due to the complexity of S6K1 expression
and regulation. Overexpressing a native
form of S6K1 does not readily yield a
catalytically active form of the enzyme
(Keshwani et al., 2008). Overexpressing
a phosphomimetic mutant kinase (Ma
and Blenis, 2009), co-overexpressing an
activating kinase (Keshwani et al.,
2008), or overexpressing a truncated ki-
nase lacking the autoinhibitory domains
(Al-Ali et al., 2007) can result in a fully
catalytically active enzyme; however,
these alterations may disrupt regulation
and substrate specificity (Pearce et al.,
2010b), potentially distancing the over-
expressed kinase from native biology.
We thus chose siRNA-mediated knock-
down to obtain independent evidence
on S6K1’s role in the regulation of neu-
rite outgrowth. Consistent with our
Figure 10. Concentrations of PF-4708671 from 1 to 10 mM increase CST regeneration after a C5/C6 dorsal hemisection. In the
DMSO control group, BDA-labeled CST axons stopped at the lesion border (DMSO control). In all three PF-4708671 treatment
groups (1, 5, and 10mM PF-4708671), numerous BDA-labeled CST axonswere found to regenerate through and beyond the lesion
gap and elongated within the distal spinal cord gray matter for considerable distances. High magnifications of boxed areas in
representative sections show CST axonal regeneration across the lesion gap only in the PF-4708671-treated groups. Neurolucida
drawings under the same representative images of the four experimental groups show detailed growth patterns of the CST axons
across and beyond the lesion gap. Bottom, Quantitative analysis of BDA-labeled CST axons regenerated at different distance zones
from the lesion site. In general, PF-4708671 significantly enhanced CST axonal regeneration beyond the lesion gap; 10 mM
4
PF-4708671 promoted higher numbers of regenerative axons
at different zones distal to the injury, but a statistically signif-
icant difference was only found at the 0–0.5 mm zone com-
pared with the 1 and 5 mM PF-4708671 groups. Data are
mean  SEM. *p 	 0.05 (two-way repeated-measures
ANOVA with Bonferroni post-test). **p 	 0.01 (two-way
repeated-measures ANOVA with Bonferroni post-test).
***p 	 0.001 (two-way repeated-measures ANOVA with
Bonferroni post-test).
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pharmacological data, we found that knocking down S6K1
promotes neurite outgrowth.
A variety of experimental approaches has led to the conclusion
thatmTORC1 activation is a key element in the induction of axon
growth (Park et al., 2010). We therefore investigated whether
mTORC1 activity is required for neurite outgrowth induced by
S6K1 inhibition. Indeed, inhibiting mTORC1 with rapamycin
reduced, but did not completely abolish, the amount of neurite
Figure 11. PF-4708671 enhanced functional recoveries of mice after a C5/C6 dorsal hemisection. Rotarod (A) forelimb drops at grid-walking (B) adhesive removal (C, D) and pellet retrieval
(E–H) show improved behavioral recoveries in groups treatedwith 1, 5, and 10mM PF-4708671, comparedwith the control groups. At one ormore time points for several tests, 10mM PF-4708671
showed significant differences from control when 1 and 5 mM treatments did not (e.g., Rotarod at 4 and 6 weeks). Data are mean SEM. *p	 0.05 (two-way repeated-measures ANOVA with
Bonferroni post-test). **p	 0.01 (two-way repeated-measures ANOVA with Bonferroni post-test). ***p	 0.001 (two-way repeated-measures ANOVA with Bonferroni post-test).
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outgrowth induced by PF-4708671. Inhibiting both mTORC1
and mTORC2 with Torin-2, on the other hand, completely ab-
rogated PF-4708671’s ability to promote neurite growth. Previ-
ous studies have shown that the mTORC2 regulates actin
polymerization and cytoskeletal dynamics (Jacinto et al., 2004;
Angliker and Ru¨egg, 2013). Mice deficient in mTORC2 exhibit
reduced actin polymerization in the hippocampus and present
with disrupted LTP and impaired memory (Huang et al., 2013).
Our results suggest that mTORC2 may also play a role in neurite
outgrowth and axon regeneration within the PI3K/PTEN net-
work.Multiple effectors and interaction partners ofmTORC2 are
known regulators of axon growth and may be involved in medi-
ating its effects, including the kinases Akt and PKC, and the
GTPaseRac1 (Ng et al., 2002; Sivasankaran et al., 2004; Park et al.,
2008; Quinn et al., 2008; Oh and Jacinto, 2011).
The strong regulation of neurite growth by manipulation of
S6K1 suggests that phosphorylation of S6, S6K1’s substrate, is
important in neurite outgrowth. Despite the large number of
studies using phosphorylation of S6 as amarker for protein trans-
lational activity, the biological significance of S6’s phosphoryla-
tion has remained controversial, suggesting the presence of
complex and likely cell-specific regulatory mechanisms (Mag-
nuson et al., 2012; Biever et al., 2015). S6 phosphorylation was
originally proposed to be required for the translation of the so-
called TOP mRNAs, which encode ribosomal protein and trans-
lation factors (Meyuhas and Dreazen, 2009), but was later found
to be merely a correlated event (Patursky-Polischuk et al., 2009).
We manipulated intracellular levels of S6 to alter availability of
the protein for phosphorylation, and found that S6 knockdown
induced neurite outgrowth in cultured neurons. Although
knocking down S6 is not equivalent to specifically decreasing the
availability of phosphorylated S6, it demonstrates that decreasing
production of S6 (and presumably, of its phosphorylated form)
can promote neurite outgrowth.
In studies of PTEN knockdown or genetic deletion, activation
of mTORC1 is consistently correlated with activation of S6K1,
and with phosphorylation of ribosomal S6. Consequently, S6
phosphorylation has been used as a marker of mTORC1 activa-
tion and, by extension, axon growth ability. Conclusions from
these studies, however, are complicated by the fact that some
investigators examined S6 phosphorylation sites that are not ex-
clusive to S6K1 (Biever et al., 2015), whereas others have not
specified which S6 phosphorylation sites were probed. In this
study, we demonstrate that perturbagens that promote neurite
outgrowth through inhibition of S6K1 activity can produce both
mTOR activation and a reduction in S6 phosphorylation. We
therefore propose that the mTOR target site on S6K1, T389S6K1,
is a more reliable marker for mTORC1 activation vis-a`-vis axon
regeneration than is S6 phosphorylation.
Because inhibiting S6K1 can induce neurite growth in cul-
tured neurons, we investigated the effect of S6K1 inhibition on
axon regeneration (and on behavioral recovery) in vivo, in a dor-
sal hemisection model of spinal cord injury. Notably, our model
produces a precise and definitive anatomical lesion that com-
pletely transects the dCST and dlCST (Sivasankaran et al., 2004;
Y. Liu et al., 2008; Zhang et al., 2013). Thus, the model can pro-
vide clean and definitive anatomical evidence of CST axonal re-
generation. We injected PF-4708671 once, bilaterally, into
sensorimotor cortex, following a previously established method
(Wang et al., 2014). This single injection had a pronounced effect
on CST regeneration across and beyond the lesion gap. Previ-
ously, a single cortical injection of Gö6976, an inhibitor of PKC
and other kinases, was shown to promote CST axonal regenera-
tion and forelimb functional recovery after a C4 dorsal hemisec-
tion in adult rats (Wang et al., 2014). It appears that delivering
these kinase inhibitors to the cell bodies of the CST neurons is
important because Gö6976 delivery to the transected CST axons
at the lesion site did not elicit axonal regeneration after a similar
injury (Sivasankaran et al., 2004; Wang et al., 2014). Supporting
the idea that the CST axons in our model were regenerating,
rather than spared, was the fact that caudal to the transection,
axons were observed in the gray matter and not in the dorsal or
lateral CST tracts. This is the same pattern observed with other
treatments that promoteCST regeneration, such as PTENknock-
out, PTEN-SOCS3 double knockout, or overexpression of VP16-
KLF7 or Sox11 (Blackmore et al., 2012; Du et al., 2015; Jin et al.,
2015; Wang et al., 2015). Although it is not possible to directly
compare experiments done in different laboratories, it is intrigu-
ing that the density and distance from the lesion of regenerating
CST fibers after a single PF treatment appear to equal or exceed
axon growth observed with PTEN knockout, or with overexpres-
sion of VP16-KLF7 or Sox11 (Wang et al., 2011; Blackmore et al.,
2012; Zukor et al., 2013; Jin et al., 2015). In this context, a single
injection of a small-molecule inhibitor provides advantages over
these direct manipulations of gene expression because it is con-
venient and easier to produce and deliver.
CST damage in rodents causes deficits primarily in fine con-
trol of the forelimbs, which is required for grasping and holding
objects (Anderson et al., 2007; Courtine et al., 2007). We per-
formed a variety of behavioral assessments to investigate the re-
covery of forelimb function following dorsal spinal hemisection.
Using injection of PF-4708671 to inhibit S6K1, we found im-
provements in functional outcomes for tests of pellet retrieval,
grid walking, Rotarod, and adhesive removal, with clear evidence
of a dose–response relationship. These tasks measure different
aspects of sensorimotor function, suggesting that S6K1 inhibi-
tion in corticospinal neurons helps to rebuild the neural network
controlling forelimb movements. Because a number of the func-
tional improvements associatedwith PF-4708671 administration
were evident as early as 1 week after injury, the relationship be-
tween regeneration of CST axons beyond the injury site and re-
covery of function may be complex and multifactorial.
The fact that single PF-4708671 injections into sensorimotor
cortex allow extensive axon growth beyond a spinal cord lesion
raises the possibility that strong inhibition of S6K1 (and activa-
tion of mTOR) produces long-term changes in the intrinsic state
of the CST neurons. Indeed, activation of the mTOR pathway, in
addition to effects on protein synthesis, is known to affect gene
transcription by a variety of mechanisms (Laplante and Sabatini,
2013). It may be that treatment of cortical projection neurons
with PF-4708671 can lead to sustained changes in transcription
factor activity and/or in epigenetic regulation. If so, it would be
important to understand the mechanisms underlying these
longer-term changes.
Although our data provide specific evidence on S6K1’s in-
volvement in regulating axon growth, we cannot rule out a role
for S6K2. Under normal conditions, S6K1 and S6K2 have distinct
biological roles and subcellular localization patterns (Pardo and
Seckl, 2013). However, knockout studies suggest that the two
isoforms have overlapping functions, and that S6K2 can partially
compensate for the S6K1 deletion (Pende et al., 2004). It will be
interesting to investigate whether S6K2 can compensate for S6K1
inhibition in the context of axon growth promotion, andwhether
simultaneous targeting of both isoforms is required for long-
term treatment efficacy.
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Apotential advantage of targeting S6K1, comparedwith phar-
macological or genetic inhibition of PTEN, is that it can induce
mTOR activation and transient increases in axon growth and
regeneration, without the potentially tumor-promoting effects of
PTEN inactivation (Song et al., 2012). The potential use of S6K1
inhibitors as drugs for neurodegeneration is further encouraged
by the fact that S6K1 inhibitors are in Phase III clinical trials for
other nononcological indications, such as liver cirrhosis and in-
sulin resistance (Hameed and Terrault, 2016). Our results, to-
gether, implicate S6K1 as a potential target for drugs that improve
axon regeneration and functional recovery following CNS injury.
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